Is Ribociclib an imported drug?

Ribociclib/Calilon (Ribociclib) is an original drug developed by an international pharmaceutical company. It is specially used for patients with hormone receptor-positive (HR+), HER2 -negative advanced or metastatic breast cancer. It blocks cancer cell cycle progression by selectively inhibiting CDK4/6 , thereby delaying tumor growth. Riboxil has been officially launched in the country and is included in the medical insurance catalog, so it is an imported drug. Imported drug status means that its production, registration and clinical application follow strict international quality standards to ensure that the drug's active ingredients, release characteristics and bioavailability are consistent with the original research trials.

The advantages of imported drugs are not only reflected in the stability of drug quality and efficacy, but also in the security and accessibility of the supply chain. Domestic patients can avoid the risk of unknown drug sources or counterfeit drugs by purchasing Riboxil through regular hospital and pharmacy channels. Compared with imported drugs that are not covered by medical insurance, the medical insurance coverage of Riboxil reduces the financial pressure of long-term treatment on patients, making it easier for patients to accept and follow the treatment plan in clinical practice. In addition, imported drugs are also more complete in terms of patient education and medication guidance. Overseas R&D companies usually provide detailed follow-up guidelines and side effects management suggestions, which help patients maintain good compliance during long-term treatment.

Both clinical guidelines and real-world data show that Riboxiclib has significant efficacy in highly resistant HR+HER2- advanced breast cancer. Compared with conventional chemotherapy or other oral targeted drugs, patients can achieve longer progression-free survival. After being launched in China, its status as an imported drug not only ensures the quality of the drug, but also makes it easier for patients to obtain standardized management and follow-up services during long-term treatment. Combined with doctor's guidance and regular testing, patients can effectively reduce the incidence of side effects while controlling tumors, and achieve safe and efficient treatment goals.

Reference: https://us.kisqali.com/